In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it
Homozygous SLC2A9 Mutations Cause Severe Renal Hypouricemia
Most protocols last 46 weeks, but duration depends on the injury, health goals, and medical advice
The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux, and abdominal discomfort
Instead, they persist, making even simple, day-to-day routines extremely difficult and frustrating
doi: 10.4082/kjfm.2016.37.6.359